**12-week, multicentre, randomized, double-blind, parallel-group, placebo-controlled studies**

- **Pre-randomization period**
  - **Screening Period**
  - **Run-in period**
- **12-week double-blind treatment period**
  - Glycopyrrolate 15.6 µg BID via Neohaler®
  - Placebo BID via Neohaler®
- **30-day safety Follow-up period**

- **Randomization (1:1)**
  - Day –21 to –15*
  - Day –13 to –1
  - Day 1 to 85
  - Day 86 to 116